What Gefitinib Treats: Main Uses and Benefits

Gefitinib is a targeted therapy used primarily for the treatment of specific types of cancer. Unlike traditional chemotherapy, which attacks all rapidly dividing cells, gefitinib is designed to interfere with specific molecular pathways that allow cancer cells to grow and spread.

Non-Small Cell Lung Cancer (NSCLC)

The primary use of gefitinib is for the treatment of locally advanced or metastatic non-small cell lung cancer. It is specifically indicated for patients whose tumors have certain genetic mutations in the epidermal growth factor receptor (EGFR).

• EGFR Mutations: Gefitinib is most effective in patients with activating mutations in the tyrosine kinase domain of the EGFR. These mutations cause the receptor to be constantly active, signaling the cancer cells to multiply uncontrollably.
• First-Line Treatment: In many cases, it is used as a first-line treatment for patients newly diagnosed with advanced NSCLC harboring these specific mutations.

Mechanism of Action

Gefitinib belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). It works by binding to the adenosine triphosphate (ATP) binding site of the EGFR tyrosine kinase. By blocking this site, the drug prevents the activation of the receptor, effectively cutting off the signaling pathway that promotes tumor cell survival and proliferation.

Clinical Benefits

The goal of treatment with gefitinib is to manage the progression of the disease and improve the quality of life for patients with EGFR-mutated lung cancer. Potential benefits include:

• Tumor Shrinkage: Many patients experience a significant reduction in the size of their tumors, a response known as objective response rate.
• Progression-Free Survival: The medication can increase the length of time a patient lives without the cancer worsening.
• Symptom Management: By controlling tumor growth, gefitinib can help alleviate symptoms associated with lung cancer, such as shortness of breath, cough, and chest pain.
• Targeted Approach: Because it targets specific receptors found more abundantly on cancer cells, it offers a different therapeutic profile compared to broad-spectrum cytotoxic chemotherapy.

Eligibility Map: Who can and cannot use Gefitinib

This section outlines the official eligibility and non-eligibility requirements for Gefitinib, based strictly on governmental regulatory documents.

---

Who Cannot Use Gefitinib (Contraindications and Restrictions)

Population/Condition	Eligibility Status	Special Consideration/Restriction
Hypersensitivity	Contraindicated	Known allergy to gefitinib or any excipients.
Breastfeeding Women	Contraindicated	Must discontinue breastfeeding during treatment.
Pregnancy	Use is not recommended	Females of reproductive potential must use effective contraception during treatment and for at least two weeks after the final dose.
Pediatric Population (<18 years)	Use not established	Safety and efficacy have not been established.
Severe Hepatic Impairment	Discontinuation is required	Patients with severe hepatic impairment (Child-Pugh C) should discontinue use.
Severe Renal Impairment	Use is restricted	Caution is advised; data are limited for patients with creatinine clearance le 20 mL/min.
Confirmed Interstitial Lung Disease (ILD), Gastrointestinal Perforation, or Persistent Ulcerative Keratitis	Permanent Discontinuation	Use must be permanently stopped if any of these conditions are confirmed or developed.
Hereditary Disorders	Use is not recommended	Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine (due to the lactose excipient).

---

Who Can Use Gefitinib

Gefitinib is indicated for use in adult patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors harbor specific Epidermal Growth Factor Receptor (EGFR) activating mutations, such as exon 19 deletions or exon 21 (L858R) substitution mutations. The presence of these specific mutations must be confirmed by an approved diagnostic test prior to initiating first-line therapy. No dosage adjustment is required for the geriatric population or for mild-to-moderate renal impairment. Patients with moderate hepatic impairment (Child-Pugh B) require close monitoring.

Interactions with other medicines and products

The regulatory information for Gefitinib identifies interaction patterns categorized by their effect on drug exposure and specific pharmacodynamic risks.

pH-Dependent Absorption: Gefitinib's absorption is dependent on gastric acidity. Co-administration with Proton Pump Inhibitors (PPIs) should be avoided when possible, as they cause a sustained reduction in Gefitinib plasma concentrations. Administration of H2-Antagonists and Antacids requires mandatory temporal separation of at least six hours from the Gefitinib dose to mitigate this reduction in exposure.

Metabolic and Enzyme Interactions: Gefitinib is principally metabolized by the CYP3A4 enzyme. The use of Strong CYP3A4 Inducers (e.g., Rifampicin, or the herbal product St John's Wort) must be avoided, as they lead to substantial reductions in Gefitinib exposure. Conversely, Strong CYP3A4 Inhibitors (such as Itraconazole) significantly increase Gefitinib plasma concentrations, necessitating cautious use. Furthermore, Gefitinib is documented as an inhibitor of the P-gp and BCRP transporters, and a weak inhibitor of CYP2D6.

Pharmacodynamic and Specific Risks: An officially documented interaction with Warfarin and other anticoagulants requires regular monitoring of Prothrombin Time (PT) or INR due to reports of INR elevations and bleeding events. Co-administration with NSAIDs or corticosteroids is noted in official labeling as a risk factor for gastrointestinal perforation. Caution is required in patients with moderate or severe hepatic impairment, who show increased Gefitinib exposure, which may enhance the significance of co-administered interactions.

Selective Inhibition of the Epidermal Growth Factor Receptor (EGFR) Kinase

Gefitinib functions as a small-molecule, competitive inhibitor of the intracellular tyrosine kinase (TK) domain of the Epidermal Growth Factor Receptor (EGFR). The drug binds reversibly to the Adenosine Triphosphate (ATP) binding site, preventing the receptor's required autophosphorylation and subsequent activation. This mechanism results in the suppression of the receptor's tyrosine kinase activity.

Disruption of Cellular Survival and Proliferation Cascades

The inhibition of EGFR-TK suppresses critical downstream signals, notably the PI3K/Akt and RAS/MEK/ERK pathways, which regulate cell survival and growth. This loss of pro-survival signaling alters the intracellular regulatory state, leading to cell cycle arrest and programmed cell death (apoptosis). The resulting physiological consequence is the inhibition of cell proliferation within the targeted cell population.

Mechanism Dependence on Specific Receptor Mutations

The mechanism exhibits higher functional affinity against cells with specific EGFR-activating mutations (e.g., exon 19 deletions) than against the wild-type receptor. The mechanism is constrained by the emergence of acquired resistance mutations, such as the T790M substitution, which alters the binding site and diminishes the drug's competitive advantage.

How to use Gefitinib: Administration Guidelines

Gefitinib is a medication administered orally as a 250 mg film-coated tablet. The standard use involves taking the 250 mg dose once daily at approximately the same time each day, and it may be taken with or without food. This daily intake is generally maintained continuously until disease progression or other specific endpoints are reached, as defined by the overall treatment protocol.

The tablet should be swallowed whole; however, for patients who cannot swallow solids, the 250 mg tablet may be dispersed in 4 to 8 ounces (120–240 mL) of non-carbonated water for immediate oral or nasogastric tube administration. The protocol requires that the container used for dispersion be rinsed with additional water, and this rinse must also be consumed immediately to ensure the full dose is received. The tablet must not be crushed during this preparation.

If a dose is missed, it should be taken immediately unless the time to the next scheduled dose is less than 12 hours away, in which case the missed dose must be skipped, and taking a double dose is prohibited. While no dosage adjustment is generally required for older adults or those with mild to moderate renal or hepatic impairment, a temporary increase to a 500 mg dose once daily is required when Gefitinib is co-administered with certain strong CYP3A4-inducing medications.

Evidence for Gefitinib as Initial Monotherapy in Advanced NSCLC

Research examined Gefitinib in a first-line setting for adults diagnosed with advanced non-small cell lung cancer (NSCLC) who carried an Epidermal Growth Factor Receptor (EGFR) activating mutation. Studies monitored time-to-event outcomes like Progression-Free Survival (PFS), and tracked tumor response rates (ORR) and Overall Survival (OS). The studies monitored PFS measurements, and patterns were observed when comparing the Gefitinib arm to the chemotherapy arm. Findings regarding Overall Survival were mixed, and subsequent analyses noted that post-study treatments may have been associated with how OS was ultimately measured and reported. Studies also tracked Quality of Life (QoL) metrics.

---

Evidence for Gefitinib in Previously Treated Advanced NSCLC

Gefitinib was evaluated in adults with advanced NSCLC who had progressed despite prior chemotherapy. The research examined short-term symptom changes and measured Objective Response Rate (ORR) and Overall Survival (OS), comparing Gefitinib against best supportive care or placebo. Measurements of Overall Survival did not show a clear, consistent pattern when compared to best supportive care in the largest trials that included the overall unselected patient population. Data show patterns related to outcomes related to physical discomfort and daily functioning or activity level in these analyses.

---

What is Still Uncertain About Gefitinib Research

Comparative evidence is not available for direct, randomized trials against all currently available targeted therapies. Research provides limited context for long-term outcomes, as follow-up durations were limited in many of the initial trials. Data for certain groups remain insufficient, such as those with rare EGFR mutations or significant comorbidities. Findings were mixed in some trials regarding overall survival in unselected patient populations, and research is ongoing to contextualize these findings within current treatment standards. Study results reflect the specific conditions under which they were conducted and apply only to the groups studied.

Key Studies & References

1. WHO Model Lists of Essential Medicines (23rd list)

Common questions about Gefitinib (FAQ)

---

Q: Why is Gefitinib sometimes referred to as 'Iressa'?

Gefitinib is the non-proprietary, or generic, name for the active medicine. The name 'Iressa' is the registered proprietary or brand name under which the product has been previously or is currently marketed in certain regions, according to official labeling.

---

Q: What is the success rate of Gefitinib in clinical trials?

Official studies measure outcomes like the Objective Response Rate (ORR), which is the proportion of patients whose tumors shrank. Official reports from clinical trials, such as the IFUM study, indicate that the ORR was observed to be approximately 50% in previously untreated patients with EGFR mutation-positive NSCLC. These findings reflect the results observed in the specific study groups.

---

Q: How is the dose of Gefitinib typically determined?

The official product information states that the standard dose for adults is a fixed amount of 250 mg taken once daily. This dosage is not typically based on a patient’s weight, height, or other individual physical factors. Dose adjustments are generally only required to address specific drug interactions or poorly tolerated side effects.

---

Q: What is the difference between Gefitinib and Osimertinib?

Both medicines are types of tyrosine kinase inhibitors (TKIs) used for EGFR-positive Non-Small Cell Lung Cancer (NSCLC). Regulatory documents categorize Gefitinib as a first-generation TKI. Osimertinib is described as a third-generation TKI that can target the common acquired resistance mutation (T790M) sometimes seen after treatment with first-generation medicines.

---

Q: Does Gefitinib work right away, or does it take time?

Pharmacokinetic data indicates the medicine reaches its highest concentration in the bloodstream within three to seven hours after taking the oral dose. However, the medicine’s effect on the tumor is a gradual process. Clinical response, such as tumor shrinkage or stabilization, is measured over a period of many months in clinical trials.

---

Q: Can certain foods or supplements interfere with Gefitinib?

Official documents advise that the herbal supplement St John's Wort must be avoided because it can significantly lower the concentration of Gefitinib in the bloodstream. Conversely, regulatory documents state that the medicine can be taken with or without food, as food does not change how the drug is absorbed.

---

Q: Is hair loss a common side effect of Gefitinib?

According to the official product information, alopecia (hair loss) is listed as a Common adverse reaction. This finding indicates that it has been reported in clinical studies in approximately 1% to 10% of patients receiving the medicine.

---

Q: Does Gefitinib cause weight gain or loss?

The safety profile frequently documents anorexia (decreased appetite) as a very common side effect. Due to the potential for decreased appetite, weight changes, including weight loss, have been reported.

---

Q: Are there any long-term effects of taking Gefitinib?

The safety profile documents risks based on the duration of clinical trials. While the official information notes serious events that can occur, research summaries indicate that long-term effects beyond the original study durations may not be fully established.

---

Q: How long after stopping Gefitinib do the side effects usually go away?

Gefitinib has a long half-life, meaning it remains in the body for an extended period after the last dose. While most common side effects are reversible once treatment is discontinued, the exact time they take to resolve is highly variable, depending on the specific side effect.

---

Q: What if I have an existing heart condition; can I still take Gefitinib?

Official information generally indicates that individuals need to disclose all pre-existing health conditions to their healthcare provider. While a uniform contraindication is not listed for common heart conditions, official warnings often highlight that symptoms like difficulty breathing may require investigation.

---

Q: Does taking Gefitinib affect blood pressure?

Official documents reviewing adverse reactions have noted that certain cardiovascular events were reported during clinical studies. However, a common adverse reaction of changes in blood pressure, either an increase or a decrease, is typically not listed among the most frequent side effects.

---

Q: Are there dietary restrictions specifically for the skin rash side effect?

Patient-focused materials from regulatory bodies do not typically specify dietary restrictions as a method to manage the common skin rash. General care advice, such as good hygiene and avoiding excessive sun exposure, is often mentioned for managing the dermatological effects.

---

How to Store and Dispose of Gefitinib

Gefitinib tablets require strict environmental control to maintain product stability, as documented by regulatory authorities.

Storage Requirements

Temperature: Store at controlled room temperature, which is between 20 C and 25 C (68 F to 77 F). The medicine must be stored away from excess heat and moisture and should be protected from light.

Protection: Keep the medicine in the original container and ensure the container is tightly closed. It is mandatory to store Gefitinib out of the sight and reach of children.

Disposal Instructions

Unused or expired Gefitinib must not be disposed of in household trash or via wastewater. Disposal of the tablets and container must be managed according to local pharmaceutical waste regulations.